

**Premier Research Services, Charlotte, NC**  
**BIBLIOGRAPHY of Peer-Reviewed VTE Publications**  
**2004-2009**

1. Amin A, **Stemkowski S**, Lin J, **Yang G**. [Appropriate prophylaxis in hospitalized cancer patients](#). *Clin Adv Hematol Oncol* 2008 (Accepted).
2. Amin A, **Stemkowski S**, Lin J, **Yang G**. [Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis?](#) *J Thromb Haemost* 2008; 99(4): 796-7.
3. Amin A, **Stemkowski S**, Lin J, **Yang G**. [Thromboprophylaxis rates in US medical centers: success or failure?](#) *J Thromb Haemost* 2007; 5: 1610-6.
4. Deitzelweig S, Lin J, Hussein M, Battleman D (non-Premier authors). [Are surgical patients at risk of venous thromboembolism currently meeting the surgical care improvement performance target goal for appropriate and timely prophylaxis?](#) [Abstract]. CHEST, Philadelphia, PA, October 2008.
5. Geno J, Merli GJ, Ferrufino CP, Lin J, Hussein M, Battleman D (non-Premier authors). [Low-molecular-weight heparin reduces the cost of venous thromboembolism treatment compared with unfractionated heparin in US hospitals](#) [Abstract]. American Society of Hematology (ASH), Atlanta, GA, December, 2007 (*Blood* 2007; 110(11): #1860).
6. Merli GJ, Ferrufino C, Lin J, Hussein M, Battleman D (non-Premier authors). [Total hospital-based costs of enoxaparin or fondaparinux prophylaxis in patients at risk of venous thromboembolism](#) (Abstract). CHEST, Philadelphia, PA, October 2008.
7. Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E (non-Premier authors). [Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery](#). *Am J Health-Syst Pharm* 2007; 64(22): 2349-55.